All the Active Ingredient Drugs
EGFR Inhibitor, Monoclonal Antibody. Cetuximab 5 mg/ml. VIAL (I.V. infus.): 10 ml, 20 ml, 50 ml, 100
ml. Initial: 400 mg/m2, foll. by 1 x wkly
dose: 250 mg/m2.
Dosage must be individ. adjust.
according to pt. med. cond.
Tmt. of pts. with (EGFR)-expressing, RAS
wild-type metast. colorectal canc. incomb.
with irinotecan-based chemot., in 1st -line
in comb. with FOLFOX, as a single agent
in pts. who have failed oxaliplatinand
irinotecan- based ther. and whoare
intoler. to irinotecan. Tmt. of pts. With
squamous cell canc. of the head and neck
(SCCHN), in comb. with rad. ther.forlocal.
advanced dis., in comb. With platinumbased
chemo. for recur. and/or metast.
dis., as a single agent after fail. of
platinum-based chemo. for recur.and/or
C/I: Severe hypersens, The comb. With
oxaliplatin-cont. chemot. is contraindic.
for pts. with mutant RAS metast.
colorectal canc. (mCRC) or for whom
RAS mCRC status is unknown.
Contraind. for concom. used chemot.
agents or rad. therapy must be
considered before init. of comb. tmt.